Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
Bone mineralization can fail when alkaline phosphatase (ALP), the enzyme that clears mineralization inhibitors like inorganic pyrophosphate from bone matrix, is deficient or underactive, allowing pyrophosphate to build up and block calcium phosphate crystal formation. Low ALP most often points to hypophosphatasia, a genetic ALPL mutation causing rickets in children, osteomalacia in adults, dental loss, and fractures, but it can also stem from zinc or magnesium deficiency (both essential ALP cofactors), hypothyroidism, severe anemia, malnutrition, celiac disease, Wilson disease, or medications such as bisphosphonates, corticosteroids, and denosumab. Because ALP requires zinc, magnesium, and an alkaline environment to function, deficiencies in these cofactors quietly impair bone hardening even without genetic disease, and low ALP paired with normal or high calcium and phosphate is a key diagnostic clue that distinguishes it from vitamin D deficiency, where ALP typically runs high. Treatment depends entirely on the cause: enzyme replacement with asfotase alfa for hypophosphatasia, cofactor repletion for nutritional causes, thyroid hormone for hypothyroidism, and avoiding antiresorptive drugs that further suppress bone turnover. There are several important nuances to consider, including why standard vitamin D and calcium supplementation can worsen some cases. See below to understand more.
Last reviewed for medical accuracy: 08/18/2026
Given that low ALP is easy to overlook on routine labs and its causes range from reversible nutrient deficiencies to serious genetic disease, understanding your specific pattern of symptoms matters before assuming a treatment path. A free, instant, online symptom check can help you organize what you are experiencing, surface questions worth raising with your clinician, and clarify whether bone pain, dental problems, or unexplained fractures warrant urgent evaluation.Bone mineralization fails when alkaline phosphatase (ALP), the enzyme that clears mineralization inhibitors like inorganic pyrophosphate from bone matrix, is deficient or underactive, letting pyrophosphate accumulate and block calcium phosphate crystal formation. Low ALP most often signals hypophosphatasia, a genetic ALPL mutation causing rickets in children, osteomalacia in adults, premature tooth loss, and fractures, but it can also arise from zinc or magnesium deficiency (both essential ALP cofactors), hypothyroidism, severe anemia, malnutrition, celiac disease, Wilson disease, or drugs like bisphosphonates, corticosteroids, and denosumab. Because ALP needs zinc, magnesium, and an alkaline environment to work, quiet cofactor deficiencies can impair bone hardening without any genetic disease, and low ALP alongside normal or high cal
Bone mineralization is the process by which minerals such as calcium and phosphate are deposited into the bone matrix, giving bones their strength and structure. When this process fails, bones become weak, prone to fractures, and can lead to a range of health issues. One key player in mineralization is the enzyme alkaline phosphatase (ALP). Low ALP levels can signal an underlying problem—among the most important is hypophosphatasia (HPP). This article will help you understand why bone mineralization fails, the truth about low ALP, and practical next steps, especially if you suspect HPP in adults.
Low serum ALP levels are less common than high ALP, but when present they warrant attention. Common causes include:
If your lab work shows persistently low ALP and you have bone pain or fractures, it’s important to consider HPP, especially if other causes have been ruled out.
HPP is a rare, inherited metabolic bone disease caused by mutations in the ALPL gene, which encodes tissue-nonspecific alkaline phosphatase (TNSALP). Although often diagnosed in infancy or childhood, mild forms can go unrecognized until adulthood.
Some adults have a very mild form and may only present with dental issues or non-specific bone pain. Because HPP in adults can mimic osteoporosis or osteomalacia, it’s sometimes misdiagnosed.
A careful diagnostic work-up is essential to distinguish HPP from other causes of low ALP and bone disease.
While there is no cure for HPP, several treatments and supportive measures can improve quality of life and bone health.
Maintaining bone health and monitoring disease progression are ongoing tasks:
If you experience any of the following, it’s important to seek prompt medical attention:
You might also consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker to get personalized guidance on next steps.
Bone disorders can be complex and sometimes life-threatening if left untreated. Always speak to a doctor or qualified healthcare provider about any serious symptoms, unexpected fractures, or concerns you have about your bone health. Early diagnosis and proper management of low ALP and HPP in adults can help you maintain mobility, reduce pain, and protect overall quality of life.
(References)
* Brenton DP, Krywawych S. Hypophosphatasia. Clin Rheum Dis. 1986 Dec;12(3):771-89. PMID: 3078782.
* Warnes TW. Alkaline phosphatase. Gut. 1972 Nov;13(11):926-37. doi: 10.1136/gut.13.11.926. PMID: 4566959; PMCID: PMC1412412.
* Mornet E. Hypophosphatasia. Best Pract Res Clin Rheumatol. 2008 Mar;22(1):113-27. doi: 10.1016/j.berh.2007.11.003. PMID: 18328985.
* Rockman-Greenberg C. Hypophosphatasia. Pediatr Endocrinol Rev. 2013 Jun;10 Suppl 2:380-8. PMID: 23858621.
* Linglart A, Biosse-Duplan M. Hypophosphatasia. Curr Osteoporos Rep. 2016 Jun;14(3):95-105. doi: 10.1007/s11914-016-0309-0. PMID: 27084188.
* Whyte MP, Simmons JH, Moseley S, Fujita KP, Bishop N, Salman NJ, Taylor J, Phillips D, McGinn M, McAlister WH. Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial. Lancet Diabetes Endocrinol. 2019 Feb;7(2):93-105. doi: 10.1016/S2213-8587(18)30307-3. Epub 2018 Dec 14. PMID: 30558909.
* Vimalraj S. Alkaline phosphatase: Structure, expression and its function in bone mineralization. Gene. 2020 Sep 5;754:144855. doi: 10.1016/j.gene.2020.144855. Epub 2020 Jun 6. PMID: 32522695.
* Villa-Suárez JM, García-Fontana C, Andújar-Vera F, González-Salvatierra S, de Haro-Muñoz T, Contreras-Bolívar V, García-Fontana B, Muñoz-Torres M. Hypophosphatasia: A Unique Disorder of Bone Mineralization. Int J Mol Sci. 2021 Apr 21;22(9). doi: 10.3390/ijms22094303. Epub 2021 Apr 21. PMID: 33919113; PMCID: PMC8122659.
* Reis FS, Lazaretti-Castro M. Hypophosphatasia: from birth to adulthood. Arch Endocrinol Metab. 2023 May 25;67(5):e000626. doi: 10.20945/2359-3997000000626. PMID: 37249457; PMCID: PMC10665056.
* Kishnani PS, Rehder C, Ozono K, Pérez-López J, Del Angel G, Mowrey WR, Balasubramanian M, Högler W, Rush ET. Revisiting the Genetics of Hypophosphatasia. J Inherit Metab Dis. 2025 Nov;48(6):e70083. doi: 10.1002/jimd.70083. PMID: 41047464; PMCID: PMC12497681.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.